Perimenopause: A Functional Medicine Guide for Women

Perimenopause is the multi-year hormonal transition that precedes menopause — the gradual decline in ovarian function during which estrogen, progesterone, follicle-stimulating hormone (FSH), and luteinising hormone (LH) shift erratically before periods stop for good. It is distinct from menopause itself, which is a single point in time defined as 12 consecutive months without a menstrual period. Perimenopause typically begins in a woman's early to mid-40s, though for some it starts in the late 30s, and can last anywhere from a few months to a decade. During this window, cycles often remain regular while symptoms — sleep disruption, mood changes, cognitive fog, weight redistribution — begin to surface and are frequently misattributed to stress, ageing, or thyroid dysfunction.

In this article

• How perimenopause differs from menopause, and why the distinction matters clinically
• The STRAW+10 staging framework and where most women find themselves
• A 34-symptom inventory the field now recognises
• How long the perimenopausal window typically lasts — and why ethnicity influences that
• Why standard primary-care labs frequently look normal during perimenopause
• The functional testing categories a deeper workup may include
• What functional medicine practitioners look for, plus one patient's experience

What perimenopause actually is — a transition, not a switch

Perimenopause is best understood as a moving biological state rather than a discrete event. Ovarian follicle reserve declines steadily from a woman's mid-30s; as fewer follicles respond to FSH each cycle, anovulatory cycles become more common, progesterone production becomes inconsistent, and estradiol (E2) begins to fluctuate widely — sometimes spiking to levels higher than those seen in earlier reproductive years before dropping sharply. The Menopause Society defines menopause itself as the date of the final menstrual period, confirmed retrospectively after 12 months of amenorrhoea. Everything before that confirmed date — symptoms, cycle changes, hormonal volatility — falls within perimenopause.

This distinction matters clinically. Many women presenting in their 40s are told they are "too young" for menopause and that nothing is wrong because periods are still happening. The published staging literature contradicts this framing. The Stages of Reproductive Aging Workshop + 10 (STRAW+10), published in 2012 in The Journal of Clinical Endocrinology & Metabolism, formally identifies multiple stages before the final menstrual period during which a woman is unambiguously in transition — regardless of whether cycles still occur monthly. Recognising perimenopause as a stageable physiological process, rather than waiting for periods to stop, is what allows earlier and more accurate clinical conversations.

Three pieces of physiology drive the transition. First, antral follicle count and anti-Müllerian hormone (AMH) — markers of remaining ovarian reserve — decline progressively from the mid-30s onward, accelerating after age 37 or 38. Second, as fewer follicles respond, the hypothalamic-pituitary axis compensates by secreting more FSH, which itself fluctuates considerably from cycle to cycle and from week to week within a cycle. Third, ovulation becomes intermittent: cycles that look superficially normal on a calendar can be anovulatory, producing no corpus luteum and therefore no meaningful luteal-phase progesterone. The clinical consequence is that progesterone often declines years before estradiol does — which is why sleep, anxiety, and luteal-phase symptoms frequently appear in women who still cycle every 28 days.

Estradiol behaviour during the transition is counterintuitive. Rather than declining smoothly, estradiol often produces wide swings, including supraphysiologic peaks during the late-reproductive and early-transition stages. Harlow and colleagues documented this volatility in their STRAW+10 review and noted that symptom intensity often tracks the magnitude of fluctuation rather than the absolute level. This is one reason why a woman with seemingly "adequate" estradiol on a single blood draw can still experience hot flashes, breast tenderness, and migraines: it is the rate and amplitude of change, not the static value, that drives much of the symptom picture.

The STRAW+10 framework — where you are matters

The STRAW+10 system is the international reference standard for describing reproductive ageing and is used in research, clinical guidelines, and increasingly in functional medicine practice. It divides the reproductive lifespan into seven stages anchored to the final menstrual period (FMP).

The two stages most relevant to women searching "what is perimenopause" are Stage −3 (late reproductive) and Stage −2 (early menopausal transition). In Stage −3, cycles are typically still regular — but subtle changes in flow, mood, or sleep are already present and reflect declining ovarian reserve. Stage −2 is defined by persistent variation in cycle length of seven days or more. Harlow and colleagues noted that this is the point at which most women begin experiencing recognisable vasomotor symptoms, though not all do, and the timing varies. Mapping where a patient sits on STRAW+10 is the foundation of any informed perimenopause workup.

The STRAW+10 update added important refinements over the original 2001 framework. Stage −3 was subdivided into Stage −3b (regular cycles, low AMH) and Stage −3a (subtle cycle changes, low AMH, occasionally elevated early-follicular FSH). Stage +1 was subdivided into +1a (first 12 months after the final menstrual period), +1b (the following one to two years of continued endocrine change), and +1c (the remaining three to six years of stabilisation). These subdivisions matter because symptom trajectories and cardiovascular, bone, and cognitive risk profiles differ across them — the early post-menopausal years (+1a and +1b) being a particularly active window of physiological change rather than a static endpoint.

Two other points are worth emphasising. First, the STRAW+10 framework explicitly acknowledges that staging may be modified — or unreliable — in women with prior hysterectomy, prior endometrial ablation, certain hormonal contraceptive use, polycystic ovary syndrome, or chronic illness that disrupts the hypothalamic-pituitary-ovarian axis. The criteria in those cases shift toward endocrine and ovarian-reserve markers (AMH, antral follicle count) rather than menstrual-cycle pattern. Second, calendar age alone is a poor proxy for reproductive stage. Two women aged 45 can be in completely different stages — one still in Stage −4, the other already in Stage −1 — based on individual ovarian reserve, smoking history, surgical history, and genetics.

Symptoms: not just hot flashes — the 34 commonly reported symptoms

Hot flashes and night sweats — collectively called vasomotor symptoms (VMS) — are the most-cited manifestations of perimenopause, but they account for only a fraction of what women report. The clinical literature, summarised by The Menopause Society, now recognises a much broader symptom profile. The widely circulated "34 symptoms" inventory consolidates these into a single checklist that helps clinicians and patients connect seemingly unrelated complaints to a common hormonal driver.

1. Hot flashes — reported by approximately 80% of women across the menopausal transition
2. Night sweats — present in roughly 50–70% of perimenopausal women
3. Irregular periods — near-universal in mid-to-late perimenopause
4. Heavier or lighter bleeding
5. Shortened or lengthened cycle intervals
6. Sleep-onset insomnia
7. Early-morning awakening
8. Anxiety, including new-onset panic episodes
9. Low mood or depressive symptoms
10. Irritability and rage spikes
11. Brain fog and word-finding difficulty
12. Short-term memory lapses
13. Reduced concentration
14. Fatigue not relieved by sleep
15. Headaches, including new or worsening migraines
16. Dizziness or vertigo episodes
17. Joint pain and stiffness
18. Muscle aches
19. Breast tenderness, often cyclical
20. Bloating and digestive changes
21. Weight gain, especially abdominal
22. Hair thinning on the scalp
23. Facial hair growth
24. Dry, itchy, or thinning skin
25. Formication (skin-crawling sensation)
26. Vaginal dryness
27. Dyspareunia (painful intercourse)
28. Reduced libido
29. Urinary urgency or recurrent UTIs
30. Heart palpitations
31. Tinnitus or altered hearing
32. Burning mouth or altered taste
33. Brittle nails
34. Body odour changes

Prevalence varies. Vasomotor symptoms are the most-studied: the SWAN cohort reported a median total VMS duration of 7.4 years in symptomatic women, with significant ethnic variation. Cognitive symptoms have a measurable biological substrate: estradiol modulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex, and research on the estrogen–BDNF pathway describes one mechanism behind the verbal-memory and processing-speed changes women commonly notice.

Several symptom clusters deserve specific mention because they are commonly misattributed to other diagnoses. New-onset anxiety and panic in a woman in her early-to-mid 40s, particularly one with no prior psychiatric history, is frequently a perimenopausal presentation rather than an isolated psychiatric event; the underlying mechanism involves declining progesterone, which is metabolised to allopregnanolone — a positive allosteric modulator of the GABA-A receptor. When progesterone falls or becomes erratic, GABAergic tone drops, and anxiety, irritability, and sleep-onset insomnia frequently follow. Joint pain, often presenting as morning stiffness in the hands, knees, or hips, is increasingly recognised as a perimenopausal symptom; estrogen has direct effects on synovial tissue, cartilage, and pain perception, and arthralgia is now well-documented in The Menopause Society's symptom literature. Heart palpitations — typically transient, non-sustained, and benign — are reported by approximately 25–40% of perimenopausal women and reflect autonomic shifts associated with estradiol fluctuation, although new palpitations always warrant cardiac evaluation to rule out arrhythmia.

The genitourinary syndrome of menopause (GSM) — vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs — typically emerges in late perimenopause and progresses through the post-menopausal years. Unlike vasomotor symptoms, which often improve over time, GSM is generally progressive without intervention because the underlying tissue changes are driven by sustained low estradiol rather than fluctuation. The Menopause Society guidance distinguishes GSM as a distinct clinical entity warranting separate discussion. Migraine patterns frequently change during perimenopause: women with prior menstrual migraine often experience more frequent or severe attacks during the transition before symptoms stabilise in post-menopause, while a smaller subset develops new-onset migraine in their 40s for the first time.

How long does perimenopause last? (SWAN cohort data)

The Study of Women's Health Across the Nation (SWAN) is the largest and longest-running multi-ethnic longitudinal study of the menopausal transition. SWAN findings have reshaped what "normal" perimenopause looks like.

The overall menopausal transition — from the first persistent cycle irregularity to the final menstrual period — averages around four years, with a published range of approximately 0.3 to 10 years. However, when total symptom duration is measured (including post-menopausal years in which symptoms persist), the numbers are considerably longer. In the SWAN vasomotor-symptom analysis, median total VMS duration was 7.4 years across the cohort. Ethnic stratification is striking:

• African American women: median 10.1 years of vasomotor symptoms
• Hispanic women: median 8.9 years
• Non-Hispanic White women: median 6.5 years
• Chinese women: median 5.4 years
• Japanese women: median 4.8 years

SWAN also found that women whose hot flashes began while cycles were still regular or in early perimenopause experienced symptoms for a median of 11.8 years — far longer than women whose vasomotor symptoms began only after periods stopped. Subsequent SWAN analyses have described disparities in reproductive ageing and midlife health between Black and White women, including earlier onset of the transition and higher cumulative symptom burden among Black participants. These data have direct clinical implications: any framework that assumes a "standard" 4-year perimenopause underestimates the experience of a substantial subset of women.

Other factors associated with earlier onset and/or longer total duration in the SWAN literature and related cohorts include current smoking, lower educational attainment, higher baseline body mass index (which influences both onset and symptom severity through aromatase-mediated peripheral estrogen production), nulliparity, and family history of early menopause. Conversely, hormonal contraceptive use, parity, and certain dietary patterns have been associated with later age at final menstrual period in observational studies — though causal inference from these associations is limited. The clinical takeaway is that perimenopause duration is highly individual and that a woman in her mid-40s with several years of escalating symptoms is not an outlier; she is well within the published distribution.

Hormone behaviour across the perimenopause window

The table below summarises typical population-level patterns for the key reproductive hormones across the STRAW+10 stages most relevant to perimenopause. Individual values vary considerably; these are reference patterns, not diagnostic cutoffs.

Reference ranges drawn from Endocrine Society clinical practice guidelines and SWAN cohort publications. Cycle-day timing of a blood draw substantially affects FSH, estradiol, and LH values.

Why standard labs often look "normal" in perimenopause

One of the most common patient experiences in perimenopause is being told that bloodwork is "normal" while symptoms continue to escalate. There are several structural reasons for this, none of which mean the patient is imagining their symptoms.

First, perimenopausal hormone production is highly variable. Estradiol can range from undetectable to supraphysiologic levels within a single month. A single blood draw represents one moment in a fluctuating curve. The Endocrine Society's clinical practice guidelines note that FSH and estradiol values during the transition are diagnostically limited precisely because of this variability, which is why STRAW+10 staging relies primarily on menstrual-cycle criteria rather than a single hormone level.

Second, reference ranges on most standard panels are built from broad adult populations and do not account for cycle day, reproductive stage, or symptom context. A TSH of 3.8 mIU/L is flagged as normal on most lab reports, even though it sits in the upper quartile of the reference range and may not reflect optimal thyroid status in a symptomatic woman.

Third, standard primary care panels typically do not test the markers that explain perimenopausal symptoms most directly: progesterone (which often drops well before estradiol), DHEA-S, cortisol rhythm, free and total testosterone, sex hormone–binding globulin (SHBG), reverse T3, thyroid antibodies, or comprehensive iron studies. When those markers are absent from the workup, a "normal" result simply reflects the limited scope of testing — not the limits of the patient's physiology.

Fourth, several conditions that overlap with or co-occur with perimenopausal symptoms are frequently missed in a routine 15-minute primary-care visit. Subclinical or early Hashimoto's thyroiditis can produce fatigue, weight gain, cognitive slowing, and hair changes that mirror perimenopause exactly; without TPO and Tg antibodies on the panel, the autoimmune process can persist for years before TSH rises into the overtly hypothyroid range. Iron deficiency without anaemia — common in women with heavy perimenopausal bleeding — produces fatigue, cognitive symptoms, and exercise intolerance well before haemoglobin drops. Vitamin D insufficiency, B12 deficiency, and insulin resistance each contribute symptom overlay that compounds the perimenopausal picture. The clinical point is not that every symptomatic woman has all of these problems, but that the perimenopausal years are a period of physiological vulnerability in which several overlapping issues commonly converge, and a narrow lab panel rarely captures the full picture.

Functional testing options for a fuller picture

Several categories of testing can extend the clinical picture beyond what a basic metabolic and thyroid panel provides. The list below is descriptive — what each category measures — and is not a recommendation to order any specific test, which is a clinical decision made between a patient and their provider.

• Comprehensive thyroid panel. A full panel typically includes TSH, free T4, free T3, reverse T3, thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb). Reverse T3 reflects how peripheral tissues are converting T4; antibodies identify autoimmune thyroiditis (Hashimoto's) that may otherwise be missed.
• Dried-urine sex-hormone and cortisol testing (e.g., DUTCH). Dried-urine collection captures multiple data points across 24 hours and quantifies hormone metabolites — particularly estrogen metabolites (2-OH, 4-OH, 16-OH pathways) and cortisol rhythm — that serum testing does not show. The Institute for Functional Medicine summarises the rationale for metabolite-pattern testing in its functional medicine educational resources.
• Ferritin and full iron studies. Heavy or erratic perimenopausal bleeding commonly depletes iron stores. Ferritin reflects storage iron and frequently shows depletion well before haemoglobin drops into anaemia range.
• Fasting insulin and HOMA-IR. Estrogen decline is associated with reduced insulin sensitivity. Fasting glucose alone often appears normal while fasting insulin is already rising — an early signal of metabolic shift.
• Inflammatory markers. High-sensitivity CRP and homocysteine can flag systemic inflammation that may underlie joint pain, mood changes, or cognitive symptoms.
• Comprehensive stool analysis. Gut microbial composition influences estrogen recirculation via the estrobolome (the gut bacteria producing β-glucuronidase). Dysbiosis is associated with altered estrogen metabolism, though the clinical literature is still developing.

What functional medicine practitioners look for

Functional medicine is an educational and clinical framework — popularised by organisations such as the Institute for Functional Medicine — that emphasises root-cause analysis, systems biology, and the interaction between genetics, environment, and lifestyle. In the perimenopausal context, a functional workup typically considers several intersecting systems rather than treating hormonal symptoms in isolation.

Practitioners working within this framework also consider sleep architecture, stress load, environmental exposures, and dietary patterns alongside laboratory data. The point is not that every patient needs every test — most do not — but that the diagnostic aperture is wider, and decisions about what to investigate are made in the context of a patient's specific symptom pattern and stage on the STRAW+10 framework. Treatment decisions, including any discussion of hormone therapy, lifestyle modification, or referral, are made individually with a prescribing clinician. The published evidence on hormone therapy itself — including the 2017 re-analysis of the Women's Health Initiative trial (Manson et al., JAMA 2017) reporting mortality outcomes by age and time-since-menopause at initiation — is discussed in a separate article on hormone therapy considerations.

Heather's story — what comprehensive testing revealed

Heather presented after 3.5 years of escalating symptoms — debilitating headaches, brain fog, weight gain around the waist despite no change in diet, and persistent fatigue. Three previous providers had run TSH, complete blood count, and a basic metabolic panel, told her labs were "normal," and attributed her symptoms to stress and ageing. A comprehensive workup including full thyroid panel with antibodies, dried-urine sex hormone testing, fasting insulin, ferritin, and a comprehensive stool analysis revealed Hashimoto's thyroiditis (elevated TPO antibodies with high-normal TSH), significant gut inflammation, and a substantial progesterone-to-estrogen imbalance consistent with her STRAW+10 stage. Within two weeks of beginning a personalised care plan, her headaches improved. Over three months, her brain fog lifted, her energy returned, and her waist measurement reduced by 12 inches.

Heather's story is shared with her consent. Her experience is one patient's, not a typical outcome. Results in perimenopause depend on a woman's individual physiology, the specific findings on her workup, the personalised plan developed with her clinician, and her adherence to that plan over time. This case is shared to illustrate the value of expanded testing in symptomatic women whose standard labs are "normal" — not as evidence that any particular protocol will produce the same outcome for another reader.

When to consider booking a consult

The following situations are commonly cited in the menopause-medicine literature as warranting a more thorough evaluation than a basic primary-care visit. A consultation is worth considering if a woman is experiencing:

• Cycle changes lasting more than three months — shorter or longer intervals, heavier or lighter flow — particularly between ages 38 and 52
• New-onset insomnia, especially early-morning awakening, that has persisted for more than six weeks
• Anxiety, panic, or low mood that feels disproportionate to life circumstances or different in quality from previous episodes
• Cognitive symptoms — word-finding difficulty, lost trains of thought, slower processing — that are interfering with work performance
• Vasomotor symptoms (hot flashes or night sweats) of any frequency
• Weight gain, particularly abdominal, in the absence of dietary or activity changes
• Joint pain or stiffness without a clear orthopaedic cause
• Symptoms in the presence of normal primary-care labs and a sense that something has been missed
• A family history of early menopause, autoimmune thyroid disease, or osteoporosis

This list is descriptive, not diagnostic. Many of the symptoms above have differential diagnoses outside of perimenopause, which is the reason a structured workup matters.

FAQ

About the author

Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.

Medical disclaimer. This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment, or a substitute for consultation with a qualified healthcare provider. Reading this article does not establish a patient-provider relationship with Interlinked Wellness or Anna Evans, MSN, APRN, FNP-C. Always seek the advice of your physician, nurse practitioner, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this site. If you think you may have a medical emergency, call 911 or your local emergency services immediately.